Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1)
Published date:
06/19/2020
Excerpt:
Expression of EGFR and HER2 was correlated with PFS and OS in multivariate analysis; HER2 expression was correlated with the tumor response...This triplet combination is effective in terms of disease control, PFS and OS, and acceptable for safety.